P159 LONG-TERM EFFICACY OF LANADELUMAB: INTERIM RESULTS FROM THE HELP OPEN-LABEL EXTENSION STUDY

M. Riedl,M. Cicardi,J. Hao,P. Lu,H. Li,M. Manning, J. Bernstein, P. Busse,R. Tachdjian, R. Gower, H. Wedner

Annals of Allergy, Asthma & Immunology（2019）

引用 1|浏览6

暂无评分

摘要

Lanadelumab prevented attacks in patients with hereditary angioedema (HAE) during 26 weeks’ treatment in the HELP study. Long-term efficacy of lanadelumab is being evaluated in the ongoing HELP open-label extension study (OLE; NCT02741596).

查看译文

关键词

lanadelumab,efficacy,long-term,open-label

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要